- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap™ PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
| Phase 1 | Phase 2 | Phase 3 |
|---|
Azacitidine and Cedazuridine (ASTX030)
Oral DNMT inhibitor (Hematological Malignancies)
| . |
Ownership: Astex
Mechanism of Action: DNA methyltransferase (DNMT) inhibition
Indications: Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
How this therapy can help
ASTX030 is an investigational oral formulation of azacitidine + cedazuridine designed to enhance systemic bioavailability of azacitidine delivered orally to the level achieved with parenteral administration of azacitidine alone. Cedazuridine is a cytidine deaminase inhibitor and inhibits azacitidine inactivation in the gut and liver.
Clinical status
ASTX030 is being evaluated in a first-in-human Phase 1-3 clinical study in patients with MDS, CMML, other myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN), or AML.
Proprietary Products and Programs
© Astex Pharmaceuticals
All rights reserved
